Genetic Variations of Human Papillomavirus Type 16: Implications for Cervical Carcinogenesis

Kukimoto, Iwao; Muramatsu, Masamichi

doi:10.7883/yoken.jjid.2014.584

Cited by 24 publications

(20 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HPV-16 represents several intra-type variants (European, African, and Asian lineages) that are associated with risk of neoplasia developing and histological type of cancer. Accordingly, non-European lineages are more pathogenic and are responsible for more cases of AdC than SCC [45,46]. HPV infection is probably not sufficient to induce neoplastic progression, as evidenced by a low proportion of CCs that have no association with viral infection [47].…”

Section: Characteristicsmentioning

confidence: 99%

MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer

Pisarska

Baldy-Chudzik

2020

JCM

View full text Add to dashboard Cite

The regulatory functions of microRNA (miRNA) are involved in all processes contributing to carcinogenesis and response to viral infections. Cervical cancer in most cases is caused by the persistence of high-risk human papillomavirus (HR-HPV) infection. While oncogenic human papillomaviruses induce aberrant expression of many cellular miRNAs, this dysregulation could be harnessed as a marker in early diagnosis of HR-HPV infection, cervical squamous intraepithelial lesions, and cancer. In recent years, growing data indicate that miRNAs show specific patterns at various stages of cervical pathology. The aim of this review is to systematize current reports on miRNA capacity that can be utilized in personalized diagnostics of cervical precancerous and cancerous lesions. The analysis of the resources available in online databases (National Center for Biotechnology Information—NCBI, PubMed, ScienceDirect, Scopus) was performed. To date, no standardized diagnostic algorithm using the miRNA pattern in cervical pathology has been defined. However, the high sensitivity and specificity of the reported assays gives hope for the development of non-invasive diagnostic tests that take into account the heterogeneity of tumor-related changes. Due to this variability resulting in difficult to predict clinical outcomes, precise molecular tools are needed to improve the diagnostic and therapeutic process.

show abstract

Section: Characteristicsmentioning

confidence: 99%

MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer

Pisarska

Baldy-Chudzik

2020

JCM

View full text Add to dashboard Cite

show abstract

“…High-risk HPV establishes its genome as an extrachromosomal episome by infecting the basal cells in the cervical epithelium through microlesions. 7 Some molecular studies have revealed fundamental mechanisms of HPV carcinogenesis by which HPV replicates, transforms cells and evades the immune system. HPV is a nonenveloped small virus of 55 nm diameter.…”

Section: Hpv and Cervical Cancermentioning

confidence: 99%

“…The intratypic variants of same genotypes are considered quasispecies which have originated either by co-infection or by mutegenesis arising from single variant. 7,11 Have reported multiple variants of Indian specific HPV 16 (V1-V16). Although these variants carry minor genetic variations in their genome but in future these key changes could provide novel strategies for the diagnosis and clinical management of HPV 16 infections.…”

Section: Hpv and Cervical Cancermentioning

confidence: 99%

A Step towards Resolving the Mystery of HPV Vaccination: Breakthrough of Cervical Cancer

Bharadwaj

Gautam

Singhal

et al. 2018

ACP

View full text Add to dashboard Cite

Cervical cancer is the second most prevalent cancer in women worldwide, with about 500,000 cases and over 270,000 deaths estimated annually. The disease is caused due to the persistent infection of one or more type of high risk HPVs in which HPV-16/18 are the most common. In India, HPV-16 is the most prevalent type of High risk HPV associated with cervical cancer risk. In the year 2006-2007, two VLP based prophylactic HPV vaccines, Gardasil and Cervarix came into the market. Recently in 2014, a new nonavalent vaccine Gardasil9 has been licensed as the improvised form of tetravalent Gardasil by FDA. Though HPV vaccines prevent its spread and persistence but they are insufficient in reverting or eliminating the already established invasive cancers. Besides, these vaccines are also having certain limitations which includes require refrigeration, higher cost, limited serotype and efficacy is person dependent. To overcome the limitations of the available vaccines, the development of second generation vaccines e.g. capsomere based vaccines, plant based edible vaccines, recombinant live-vector vaccines, protein and peptide based vaccines, multi-epitopic based vaccines and DNA-based vaccines is under way. These vaccines will be heat stable, cost effective and may apply both in prevention and also in the treatment of cancers. It has been stated that cervical cancer is detected mainly in women older than 35 years suggesting HPV infection at a younger age and slow progression to cancer at an older age. It is really difficult to promote vaccination for younger girls in countries like India to prevent the onset of the disease because of the cultural and prestigious issues related to STDs. So there is an urging need in India for the development of therapeutic vaccine for the eradication of the devastating disease as well as to meet the global responsibility of achieving herd immunity.

show abstract

“…Our previous epidemiological studies showed that the HPV16 type, with an infection rate of 3.1%, was less common in the Chinese general population but was found most frequently in patients with cervical intraepithelial neoplasia 2 (CIN2), CIN3 and cervical cancer (31.6, 47.9 and 60.6%, respectively) [ 7 , 8 ]. Many lines of evidence have indicated that the genetic variability of the HPV16 genome contributes to HPV-driven cervical carcinogenesis [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China

Dai

Qiu

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Human papillomavirus (HPV) type 16 accounts for a larger share of cervical cancer and has been a major health problem worldwide for decades. The progression of initial infection to cervical cancer has been linked to viral sequence properties; however, the role of HPV16 variants in the risk of cervical carcinogenesis, especially with longitudinal follow-up, is not fully understood in China. Methods We aimed to investigate the genetic variability of HPV16 E6 and E7 oncogenes in isolates from cervical exfoliated cells. Between December 2012 and December 2014, a total of 310 single HPV16-positive samples were selected from women living in the Taizhou area, China. Sequences of all E6 and E7 oncogenes were analysed by PCR-sequencing assay. Detailed sequence comparison, genetic heterogeneity analyses and maximum-likelihood phylogenetic tree construction were performed with BioEdit Sequence Alignment Editor and MEGA X software. Data for cytology tests and histological diagnoses were obtained from our Taizhou Area Study with longitudinal follow-up for at least 5 years. The relationship between HPV16 variants and cervical carcinogenesis risk was analysed by the chi-square test or Fisher’s exact test. Results In this study, we obtained 64 distinct variation patterns with the accession GenBank numbers MT681266-MT681329. Phylogenetic analysis revealed that 98.3% of HPV16 variants belong to lineage A, in which the A4 (Asian) sublineage was dominant (64.8%), followed by A2 (12.1%), A1 (11.4%), and A3 (10.0%). The A4 (Asian) sublineage had a higher risk of CIN2+ than the A1–3 (European) sublineages (OR = 2.69, 95% CI = 1.04–6.97, P < 0.05). Furthermore, nucleotide variation in HPV16 E6 T178G is associated with the development of cervical cancer. Conclusion These data could provide novel insights into the role of HPV16 variants in cervical carcinogenesis risk in China.

show abstract

Genetic Variations of Human Papillomavirus Type 16: Implications for Cervical Carcinogenesis

Cited by 24 publications

References 52 publications

MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer

MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer

A Step towards Resolving the Mystery of HPV Vaccination: Breakthrough of Cervical Cancer

Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China

Contact Info

Product

Resources

About